Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Anatara Lifesciences Ltd ( (AU:ANR) ).
Anatara Lifesciences Ltd announced mixed results for its GaRP-IBS Phase II trial, with the primary efficacy endpoint not being met, though secondary endpoints showed promising results in anxiety improvement and IBS-adequate relief. The company is reviewing its direction following these results and continues to explore commercial possibilities for its GaRP product in gastrointestinal health.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focusing on significant unmet needs in human health, particularly conditions involving the complexity of the gastrointestinal tract.
YTD Price Performance: -78.00%
Average Trading Volume: 1,508,797
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.17M
See more insights into ANR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue